Olema Pharmaceuticals, Inc. (OLMA) Stock Ticker
OLMA right now
Market factors today
Unlock the full OLMA picture
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
OLMA stock facts
| Ticker symbol | OLMA |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $764.3M |
| CEO | Sean Bohen |
| Employees | 150 |
| Headquarters | San Francisco, CA, US |
| IPO date | 2020-11-19 |
| Website | www.olema.com |
What you can see for OLMA on Tickr
Live OLMA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the OLMA report.
Rankings
FAQ
What is the ticker symbol for Olema Pharmaceuticals, Inc.?
The ticker symbol for Olema Pharmaceuticals, Inc. is OLMA, listed on the NASDAQ Global Select.
What is OLMA?
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen…